HLN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Haleon PLC is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive catalysts such as hedge fund buying and analyst upgrades, the financial performance is weak, and technical indicators suggest the stock is overbought. The lack of Intellectia Proprietary Trading Signals further diminishes the case for immediate action.
The MACD is positive at 0.0602, indicating bullish momentum, but it is contracting. RSI is at 81.318, signaling the stock is overbought. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance levels (R1: 11.138, R2: 11.36), suggesting limited upside potential in the short term.
Hedge funds are significantly increasing their positions, with a 142.48% increase in buying over the last quarter. Analysts have recently upgraded the stock with raised price targets, indicating confidence in the company's future performance. The launch of Sensodyne Clinical Repair toothpaste could drive revenue growth.
The stock is overbought based on RSI, and technical indicators suggest limited short-term upside. Financial performance in the latest quarter shows a YoY revenue decline of -5.33% and a net income drop to 0, indicating weak fundamentals. No recent congress trading data or Intellectia Proprietary Trading Signals to support a strong buy case.
In 2025/Q2, revenue dropped to $2.627 billion, down -5.33% YoY. Net income fell to 0, a -100% decline YoY. However, EPS increased to 0.09, up 200% YoY, and gross margin improved to 64.51%, up 4.69% YoY.
Recent analyst upgrades include Barclays raising the price target to 420 GBp, HSBC to 430 GBp, and Jefferies to 450 GBp. Goldman Sachs added Haleon to its European Conviction List, citing expected best-in-class sales growth.
